Category Archives: Advocacy & Partnerships

CSPCP and CHPCA request exception to new standards from NAPRA

(March 4, 2019) Recently-released Model Standards for Pharmacy Compounding for Non-Hazardous Sterile Preparations from the National Association of Pharmacy Regulatory Authorities (NAPRA) stipulate that community pharmacies must use a Before Use Date of twelve hours for pre-filled medication syringes. This significantly affects our ability to provide care for patients with palliative care needs in the home, especially at end of life.

The CSPCP and Canadian Hospice Palliative Care Association jointly wrote to NAPRA on February 19, 2019, requesting an exception to this standard for palliative care. The letter describes the reasons why care is affected and what the impact is for patients, caregivers, and health care providers. Copies of the letter were sent to Health Canada, to their federal/provincial/territorial/ palliative care group, and to the heads of the provincial Sections of Palliative Medicine. We are currently awaiting a response and will provide updates when available.

Read the letter

National Framework Implementation

Representatives from the Palliative 4 Canadians (P4C) group met with Health Canada on January 30, 2019 to begin discussing implementation of the national Framework on Palliative Care in Canada. The Framework was tabled in parliament on December 4, 2018 by the Honourable Ginette Petitpas Taylor, federal Minister of Health, after a year-long consultation with many stakeholders including the CSPCP. Health Canada reported that they will now develop a Framework implementation plan that aims to action the guiding principles and goals reflected in the Framework. Their goal is to have the plan ready by late Spring 2019. Health Canada also plans to establish an Office of Palliative Care to provide high level coordination of palliative care activities going forward. P4C shared suggestions on how the Office could be structured to optimize efficiency and results.

We look forward to seeing how the implementation unfolds and the CSPCP will continue to be an active partner. It is heartening to have federal politicians and Health Canada assist all of us with improving palliative care for all Canadians.

*Canada’s four national palliative care organizations РCSPCP, CHPCA, Canadian Virtual Hospice and Pallium Canada

CSPCP DEFENDS AVAILABILITY OF HIGH STRENGTH OPIOID FORMULATIONS FOR PALLIATIVE CARE

(Dec 7, 2018) The CSPCP responded to a commentary in the CMAJ asking for a ministerial recall of high-strength opioid formulations. Thank you to CSPCP Communications Committee Member Catriona Aparicio for helping prepare the response.

CSPCP response: http://www.cmaj.ca/content/190/48/E1404/tab-e-letters#cspcp-response-to-herder–juurlinks-high-strength-opioid-formulations-the-case-for-a-ministerial-recall

CSPCP at QELCCC Palliative Care Breakfast for MPs

The Quality End of Life Coalition of Canada (QELCCC) hosted a breakfast for MPs in Ottawa on October 25th. Several CSPCP members and Board members mixed and mingled with the crowd, which included MPs, senators, and representatives from many of the QELCCC member organizations. A highlight of the event was a moving personal story shared by Paul Adams. To view an earlier written version of the story, click here.

Letter from COS, CPA and CSPCP re Atropine: Update

(Update: August 2018) Novartis/Alcon will not discontinue the sale of Atropine 1% as they had previously announced. The decision came after consideration of the joint letter that was sent in May 2018 (below).

(May 2018) The Canadian Ophthalmological Society, the Canadian Psychiatric Association, and the CSPCP sent a joint letter to Novartis/Alcon, urging them to reconsider the upcoming discontinuation of Atropine.

View letter here